Marine organisms as a source of new anticancer agents.

@article{Schwartsmann2001MarineOA,
  title={Marine organisms as a source of new anticancer agents.},
  author={Gilberto Schwartsmann and Adriana Brondani da Rocha and Roberto G. S. Berlinck and Jos{\'e} Mar{\'i}a Jimeno},
  journal={The Lancet. Oncology},
  year={2001},
  volume={2 4},
  pages={
          221-5
        }
}

Figures and Tables from this paper

Marine natural products: A lead for Anti-cancer
TLDR
This study addresses anticancer drug discovery from an evolutionary perspective and presents a series of case studies that demonstrate that the rate of anticancers drug discovery can be increased greatly by targeted screening of natural compounds from marine sources.
Marine-derived anticancer agents in clinical trials
TLDR
The authors discuss the available literature on anticancer agents that have reached clinical trials, such as didemnin B, aplidine, dolastatin-10, bryostatin-1 and ecteinascidin-743 (ET-7 43, trabectedin), as well as other promising compounds still undergoing tests in the laboratory.
THERAPEUTIC POTENCY OF ANTICANCER PEPTIDES DERIVED FROM MARINE ORGANISM
TLDR
These characteristics imply that the use of peptides and others biomolecules from marine sources has potential for the prevention and treatment of cancer and they might also be useful as molecular models in anticancer drug research.
Marine Natural Products: A Source of Novel Anticancer Drugs
TLDR
The impact of marine organisms, with particular emphasis on marine plants, algae, bacteria, actinomycetes, fungi, sponges and soft corals, and the possible molecular mechanisms behind the biological effects are presented.
MARINES AND MICROORGANISMS NATUREVOLUTION OF ANTI-CANCER AGENTS- A REVIEW
TLDR
This review highlights several marine natural products and their synthetic derivatives that are currently undergoing clinical evaluation as anticancer drugs.
Promising Activities of Marine Natural Products against Hematopoietic Malignancies
TLDR
This review is focused on marine natural products with anticancer activity against hematological tumors, highlighting recent advances and possible perspectives.
Progress in the clinical development of new marine-derived anticancer compounds.
TLDR
ET-743 (Yondelis) represents the first new agent developed against advanced pretreated soft tissue sarcoma in the past 25 years, and also harbors activity in women bearing pretreated ovarian cancer and a solid potential in combination therapy.
The Phylum Bryozoa as a Promising Source of Anticancer Drugs
TLDR
This review covers the literature for secondary metabolites isolated from marine cheilostome and ctenostome bryozoans that have shown potential as cancer drugs and highlights examples such as bryostatins, the most known class of marine-derived compounds from this animal phylum which are advancing through anticancer clinical trials due to their low toxicity and antineoplastic activity.
Natural products in anticancer therapy.
Anticancer Activity and Molecular Mechanisms of Action of Makaluvamines and Analogues
TLDR
A series of synthetic makaluvamine analogs have now been shown to inhibit cell proliferation and cell cycle progression, to induce apoptosis, and to modulate the expression of several genes such as MDM2, p21, and p53.
...
...

References

SHOWING 1-10 OF 58 REFERENCES
Marine organisms and other novel natural sources of new cancer drugs.
  • G. Schwartsmann
  • Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2000
TLDR
It can be anticipated that aquatic environment may become a potentially valuable source of novel compounds, as the world's oceans cover about 70% of the earth's surface and all except 2 of the 28 major animal phyla are represented there.
Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays
TLDR
Results point to high antiproliferative activity of aplidine and IHB in prostate cancer, and urge some caution in the clinical use of these agents because of potential neurotoxic side-effects.
Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds.
TLDR
The South-American Office for Anti-Cancer Drug Development has implemented a large-scale project of acquisition and testing of compounds isolated from South American medicinal plants, derived from the Madagscan periwinkle plant, Pacific yew Taxus brevifolia, and the Chinese tree Camptotheca acuminata.
The rational design of potential chemotherapeutic agents: Synthesis of bryostatin analogues
TLDR
A new class of bryostatin analogues which retain the putative recognition domain of the bRYostatins but are simplified through deletions and modifications in the C1—C14 spacer domain have been designed using computer models, and a convergent synthesis has been realized for the production of these recognition and spacer domains whose coupling allows for the generation of a range of analogues.
Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents.
TLDR
The search for novel antitumor agents from natural sources continues with botanists, marine biologists, and microbiologists teaming up with chemists, pharmacologists, toxicologists, and clinicians in the investigation of coral reefs, rain forests, and deep subsurface thermal vents for novel bioactive compounds.
Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.
  • T. Madden, H. Tran, J. Abbruzzese
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
TLDR
The available preclinical, pharmacological, and clinical data suggest that further study of escalated DOLA-10 dosing with cytokine support is warranted, and any antitumor activity of this novel agent is documented.
The dolastatins, a family of promising antineoplastic agents.
  • J. Poncet
  • Chemistry
    Current pharmaceutical design
  • 1999
TLDR
This study showed that dolastatin 10 exists in two different conformations corresponding to a cis-trans isomerization of a central amide bond, and elaborated hybrid molecules constituted of parts of both compounds, which locked this compound in its cis conformation.
A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
TLDR
Bryostatin 1 is immunomodulatory in vitro, and in vivo, and an investigation of the first three cycles of treatment in seven patients showed an increased IL-2-induced proliferative response in peripheral blood lymphocytes and enhanced lymphokine-activated killer (LAK) activity.
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.
  • L. Krug, V. Miller, M. Kris
  • Chemistry, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2000
TLDR
Dolastatin-10 is an agent isolated from the organism Dolabella auricularia, a shell-less mollusk known as a sea hare that has demonstrated anti-tumor effects in several preclinical models including hematologic and solid tumor malignancies.
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
TLDR
Its antitumor activity was especially potent against murine Meth A fibrosarcoma and human SC-6 stomach adenocarcinoma which were refractory to mitomycin C or cisplatin.
...
...